Loading clinical trials...
Loading clinical trials...
A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib
Conditions
Interventions
Radotinib HCl
Locations
18
Russia
Territorial State Budgetary Institution
Barnaul, Russia
Federal State Budgetary Institution of Science
Kirov, Russia
Federal State Budgetary Institution
Moscow, Russia
Hematology Centre based on City Clin. Hosp. n.a. S.P. Botkin
Moscow, Russia
Federal State Budgetary Institution
Saint Petersburg, Russia
Federal State Budgetary Institution
Saint Petersburg, Russia
Start Date
June 25, 2018
Primary Completion Date
June 30, 2026
Completion Date
December 31, 2027
Last Updated
October 28, 2024
NCT05143840
NCT06119269
NCT06423911
NCT03722420
NCT06233890
NCT04126681
Lead Sponsor
Il-Yang Pharm. Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions